Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma are both precursor conditions that can turn into multiple myeloma, a type of cancer that affects plasma cell production ...
Watch Dr. Neha S. Korde, an assistant professor in multiple myeloma service in the Division of Hematology at Memorial Sloan Kettering Cancer Center, present on MGUS/smoldering myeloma. Multiple ...
Kinetics of humoral immunodeficiency with bispecific antibody therapy in multiple myeloma. Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus ...
Patients with monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM), can progress from low- or intermediate-risk to MM in just 5 years, according to ...
The rate of MGUS among hospitalized patients over 50 was twice as high as that of the same age group in the general population. Higher rates of MGUS were prevalent among patients who had elevated ...
To date, there are no drug therapies that have been effective in treating MGUS. German investigators found that WBV increased MGUS patients’ physical performance in 3 separate types of tests, at both ...
GLP-1RA use was associate with lower risks for cardiovascular events among patients with monoclonal gammopathy of undetermined significance and type 2 diabetes. Use of glucagon-like peptide-1 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results